Katerina Kovalevskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katerina Kovalevskaya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Kovalevsky
Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
1 shared publication - Annie Aniana
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892-0520, USA
1 shared publication - Colleen B. Jonsson
Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA
1 shared publication - Dipendra Bhandari
Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
1 shared publication - John M. Louis
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892-0520, USA
1 shared publication - Jyothi Parvathareddy
Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4483-4501
Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites
Novel noncovalent SARS-CoV-2 main protease inhibitors were designed, targeting catalytic dyad and primed binding subsites. Neutron diffraction revealed new conventional and nonconventional interactions, offering insights for future inhibitor design.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4483-4501
Open AccessNoncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites
Novel noncovalent SARS-CoV-2 main protease inhibitors were designed, targeting catalytic dyad and primed binding subsites. Neutron diffraction revealed new conventional and nonconventional interactions, offering insights for future inhibitor design.